SCHEMBL2481256

SCHEMBL2481256

NC(=NO)c1cccc(N)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.55
PLG P00747 1/20 0.55
PRSS1 P07477 1/20 0.55
PRSS2 P07478 1/20 0.55
PRSS3 P35030 1/20 0.55
KDM1A O60341 9/20 0.50
PBRM1 Q86U86 1/20 0.48
RECQL P46063 2/20 0.46
CYP3A4 P08684 1/20 0.46
CASP1 P29466 1/20 0.46
NOS1 P29475 1/20 0.44
CA12 O43570 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CA14 Q9ULX7 1/20 0.43
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17730485 1.00 F2 (0.55) F2PLGPRSS1PRSS2PRSS3
SCHEMBL8312824 1.00 F2 (0.55) F2PLGPRSS1PRSS2PRSS3
SCHEMBL31650872 1.00 F2 (0.55) F2PLGPRSS1PRSS2PRSS3
SCHEMBL20114738 0.83 F2 (0.55) F2PLGPRSS1PRSS2PRSS3
SCHEMBL17354740 0.81 F2 (0.53) F2PLGPRSS1PRSS2PRSS3
SCHEMBL18891443 0.79 PBRM1 (0.55) F2PLGPRSS1PRSS2PRSS3
SCHEMBL750859 0.78 KDM1A (0.59) KDM1ARECQLCYP3A4CA12ALDH1A1
SCHEMBL8820938 0.78 KDM1A (0.59) KDM1ARECQLCYP3A4CA12ALDH1A1
SCHEMBL750858 0.78 KDM1A (0.59) KDM1ARECQLCYP3A4CA12ALDH1A1
SCHEMBL31748645 0.78 KDM1A (0.59) KDM1ARECQLCYP3A4CA12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140026782-A1 SILVER INK COMPOSITION INKTEC CO., LTD. (KR) 2014-01-30 US claimed
WO-2012144847-A2 SILVER INK COMPOSITION 주식회사 잉크테크 (KR) 2012-10-26 WO claimed
US-12501540-B2 Electronic device and manufacturing method thereof FUJIFILM CORPORATION (JP) 2025-12-16 US disclosed
US-12451440-B2 Electronic device and manufacturing method thereof FUJIFILM CORPORATION (JP) 2025-10-21 US disclosed
US-12389549-B2 Manufacturing method of electronic device FUJIFILM CORPORATION (JP) 2025-08-12 US disclosed
US-20250236954-A1 MANUFACTURING METHOD OF CONDUCTIVE FILM AND MANUFACTURING METHOD OF ELECTROMAGNETIC WAVE SHIELDING BODY FUJIFILM CORPORATION (JP) 2025-07-24 US disclosed
CN-119866391-A Method for producing conductive film and method for producing electromagnetic wave shield 富士胶片株式会社 2025-04-22 CN disclosed
US-20240425715-A1 MANUFACTURING METHOD OF CONDUCTIVE LAYER FUJIFILM CORPORATION (JP) 2024-12-26 US disclosed
US-20240424817-A1 MANUFACTURING METHOD OF CONDUCTOR, MANUFACTURING METHOD OF ELECTROMAGNETIC WAVE SHIELDING BODY, AND CONDUCTOR FUJIFILM CORPORATION (JP) 2024-12-26 US disclosed
US-20240414839-A1 MANUFACTURING METHOD OF PRINTED CIRCUIT BOARD FUJIFILM CORPORATION (JP) 2024-12-12 US disclosed
CN-118900778-A Method for manufacturing conductive layer 富士胶片株式会社 2024-11-05 CN disclosed
EP-1944305-B1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LTD (GB) 2011-10-19 EP disclosed
US-20090312325-A1 Quinoline Derivatives As Phosphodiesterase Inhibitors BALDWIN IAN ROBERT 2009-12-17 US disclosed
US-7572915-B2 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide; asthma, COPD, allergic rhinitis, or rheumatoid arthritis in a human GLAXO GROUP LIMITED (GB) 2009-08-11 US disclosed
US-7566786-B2 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2009-07-28 US disclosed
EP-1944305-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2008-07-16 EP disclosed
EP-1633748-B1 QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LTD (GB) 2008-03-05 EP disclosed
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2007-06-21 US disclosed
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors DEAN ANTHONY W 2007-03-01 US disclosed
US-20060178416-A1 Quinoline derivatives as phosphodiesterase inhibitors BARKER MICHAEL D 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178416-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A F2 2108/4885PLG 2110/4885PRSS1 171/4885
US-20090312325-A1 Quinoline Derivatives As Phosphodiesterase Inhibitors PDE3B, PDE4B, PDE4A F2 2108/4885PLG 2110/4885PRSS1 171/4885
US-20070049570-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A F2 2108/4885PLG 2110/4885PRSS1 171/4885
US-20070142373-A1 Quinoline derivatives as phosphodiesterase inhibitors PDE3B, PDE4B, PDE4A F2 2108/4885PLG 2110/4885PRSS1 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.